Turn Therapeutics (NASDAQ:TTRX) Receives “Sell” Rating from WBB Securities

Turn Therapeutics (NASDAQ:TTRX)‘s stock had its “sell” rating reissued by WBB Securities in a report issued on Monday, Benzinga reports. They currently have a $10.00 price target on the stock. WBB Securities’ price target indicates a potential downside of 26.90% from the stock’s current price.

Several other equities research analysts also recently issued reports on the company. Weiss Ratings downgraded Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Wall Street Zen raised Turn Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Finally, Zacks Research upgraded Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.00.

Turn Therapeutics Stock Up 7.8%

Shares of NASDAQ TTRX traded up $0.99 during mid-day trading on Monday, reaching $13.68. The company had a trading volume of 46,670 shares, compared to its average volume of 55,069. The company has a debt-to-equity ratio of 8.83, a quick ratio of 1.19 and a current ratio of 1.19. The company has a market capitalization of $407.53 million and a price-to-earnings ratio of -47.57. The stock has a fifty day moving average of $9.71 and a two-hundred day moving average of $6.28. Turn Therapeutics has a 12-month low of $2.57 and a 12-month high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. As a group, equities research analysts expect that Turn Therapeutics will post -0.4 EPS for the current year.

Hedge Funds Weigh In On Turn Therapeutics

Institutional investors have recently modified their holdings of the stock. Hodges Capital Management Inc. bought a new stake in shares of Turn Therapeutics during the fourth quarter valued at approximately $39,000. LPL Financial LLC acquired a new position in Turn Therapeutics during the 4th quarter worth $51,000. Tamar Securities LLC bought a new position in Turn Therapeutics in the 4th quarter valued at $59,000. Jane Street Group LLC acquired a new stake in shares of Turn Therapeutics in the 4th quarter valued at $68,000. Finally, Geode Capital Management LLC bought a new stake in shares of Turn Therapeutics during the fourth quarter worth $68,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.